论文部分内容阅读
目的：探讨增殖细胞核抗原（PCNA）表达与乳腺浸润性导管癌预后的关系。方法：用免疫组化LSAB法，对86例乳腺浸润性导管癌作PCNA（单抗PC10）检测，并与随诊资料进行比较分析。结果：1．PCNA在本组病例的表达率为69．8％22．PCNA阳性表达组与阴性表达组比较，两组在所占晚期病人比较（分别为65％与23．1％）、淋巴结转移率（86．7％与57．8％）、复发转移率（80％与50％）、2年死亡率（50％与19．2％）、5年生存率（31．7％与65．4％）几个方面均有显著差异（P＜0．001～0．005）。强阳性表达组与阴性表达组5年生存率的差异更为显著（分别为23．3％与65．4％，P＜0．0001）；3．PCNA表达结合淋巴结转移、TNM分期3个因素协同分析，对乳癌患者预后的评估有更大的意义。PCNA（－）、淋巴结（－）、TNM ⅠⅡ病例的5年生存率可达90．9％；相反，PCNA（＋），淋巴结（＋）、TNM ⅢⅣ病例的5年生存率只有13．9％（P＜0．0001）。结论：乳腺癌PCNA的表达与TNM分期、淋巴结转移、肿瘤复发及远处转移呈正相关，与预后呈负相关。PCNA是估计乳腺癌预后的一个有用的指标。
Objective: To investigate the relationship between the expression of proliferating cell nuclear antigen (PCNA) and the prognosis of breast invasive ductal carcinoma. Methods: Using the immunohistochemical method of LSAB, 86 cases of infiltrating ductal carcinoma of the breast were detected with PCNA (PCAb) and compared with follow-up data. Results: 1. The expression rate of PCNA in this group of patients was 69.8%. PCNA-positive and negative expression groups were compared between the two groups in the late-stage patients (65% and 23.1%, respectively), lymph node metastasis (86.7% and 57.8%), recurrence and metastasis (80 There were significant differences (% and 50%), two-year mortality (50% and 19.2%), and 5-year survival (31.7% and 65.4%) (P<0.001 to 0). .005). The difference in 5-year survival rate between the strong positive and negative expression groups was even more significant (23.3% and 65.4%, respectively, P<0.0001). The analysis of PCNA expression combined with lymph node metastasis and TNM staging was of greater significance in the assessment of the prognosis of breast cancer patients. The five-year survival rate for PCNA(-), lymph node(-), and TNM III cases was as high as 90.9%. In contrast, the 5-year survival rate for PCNA(+), lymph node(+), and TNM IIIIV cases was only 13.9%. (P<0.0001). Conclusion: The expression of PCNA in breast cancer is positively correlated with TNM stage, lymph node metastasis, tumor recurrence and distant metastasis, and negatively correlated with prognosis. PCNA is a useful indicator for estimating the prognosis of breast cancer.